Investor Ideas #Potcasts: #Cannabis News and #Stocks on the Move-
(CSE: $SLNG.C) (NYSE: $CGC) (CSE: $TER.C) (CSE: $MYM.C) (CSE: $CURA.C)
Delta, Kelowna, BC –May 2,
2019 (Investorideas.com Newswire) www.Investorideas.com, a global news source
covering leading sectors including marijuana and hemp stocks and its potcast
site, www.potcasts.ca release today’s edition of Investorideas.com potcastsCM -
cannabis news and stocks to watch plus insight from thought leaders and
experts.
Listen to the podcast:
Read this in full
at
Today’s podcast overview/transcript:
Good
morning and welcome to another episode of Investorideas.com “potcasts”, looking
at cannabis news, stocks to watch as well as insights from thought leaders and
experts.
In
today’s podcast I focus on a few early announcements from some interesting
companies.
SLANG Worldwide
Inc. (CSE: SLNG), a leading global cannabis consumer
packaged goods company with a robust portfolio of renowned brands distributed
across 2,600 stores in 11 US states, announced the establishment of its new
wellness-focused business division, SLANG Health and Wellness. The new business
unit will develop and market a portfolio of plant-based cannabidiol products
that will be distributed in partnership with Greenlane Holdings, Inc. (NASDAQ: GNLN) through their extensive distribution
network.
"Consumers
are increasingly interested in natural plant-based wellness products, and we've
only scratched the surface of the opportunity within cannabinoid-supported
wellness," said SLANG CEO Peter Miller. "Health and Wellness
represents a new market segment for SLANG and is a natural extension for our
portfolio of top selling products across the US and internationally. We expect
early sales to be supported by the brand awareness and customer loyalty that
we've developed within our existing portfolio over many years of innovation and
consumer
focus."
SLANG
Health and Wellness products will target a rapidly expanding and promising
consumer market that is expected to grow from US$591 million in 2018 to US$22
billion by 2022, according to The Brightfield Group. The Company will initially
focus on extending SLANG's existing industry leading portfolio of THC-dominant
products into the CBD space and will immediately launch sales of the Company's
best-selling O.penVAPE Reserve brand, to be sold as a half gram hemp-based CBD
cartridge.
Canopy Growth
Corporation(TSX: WEED) (NYSE: CGC) announced that it has acquired German-based,
Bionorica SE-founded C3 Cannabinoid Compound Company in a
transformative deal that will see established single cannabinoid medicines
brought together with the world's leading full-spectrum medical cannabis
offering.
The
all cash-acquisition for €225.9 million (CDN $342.9 million) furthers Canopy
Growth's expansion into European markets with prescription medicines and gives
the Company immediate access to a wealth of knowledge and intellectual property
that C3 has developed in its nearly 20 years of research and
development into synthetic and natural cannabis medical products.
C3's
primary medicinal offering is dronabinol, a pure chemical compound with
standardized concentrations of tetrahydrocannabinol (THC), one of the active
ingredients found in cannabis plants that is responsible for various
pharmacological effects. Dronabinol is available in Austria, Denmark, and
Germany for nausea and vomiting refractory to conventional treatment in
oncology and palliative care, and for cancer pain. In Germany, dronabinol can
be prescribed for any type of chronic pain and for any condition in palliative
care. C3 has a total of five medicines in the market and its
commercial operations generated €27.1 million (CDN $41.5 million) in 2018.
The
acquisition will allow Canopy Growth to further empower European physicians
with the knowledge and therapies drawn from the full range of synthetic to
naturally-derived cannabinoid-based medicines. Adding dronabinol to Canopy
Growth's product offering in Europe and potentially other key markets will
allow the Company's medical division, Spectrum Cannabis, to present an
expanded, medically validated suite of cannabinoid therapies to the benefit of
healthcare professionals and patients. Furthermore, C3's
infrastructure including production, distribution, and sales & marketing
significantly adds to the Spectrum Cannabis footprint in Europe, including an
expanding product line and additional reach into pharmacy and medical
specialists' networks.
TerrAscend Corp. (CSE: TER) (OTCQX: TRSSF) today announced that its manufacturing facility in
Mississauga, Ontario, Canada has been issued a Good Manufacturing Practice
certificate in accordance with the rules governing medicinal products in the
European Union.
The
EU GMP certification was awarded by the responsible agency,
Arzneimittelbehörde, in North Rhine-Westphalia, Germany. Additionally, the
Company has entered a comprehensive sales and distribution agreement with iuvo
Therapeutics GmbH, a German pharmaceutical wholesaler with a cannabis-specific import
and distribution license. TerrAscend expects to begin distribution through iuvo
this quarter.
"Just
five months ago, TerrAscend became the first North American Operator (NAO),
with scale operations in both Canada and the US. Upon commencement of shipments
this quarter, through our partner iuvo in Germany, TerrAscend will be the first
and only global cannabis operator with sales in the three largest markets in
the world," said Dr. Michael Nashat, CEO of TerrAscend. "We will
continue to expand our sales footprint going forward and will share news of
these milestones as we achieve them."
MYM Nutraceuticals
Inc., (CSE: MYM) (OTCBB: MYMMF) announced that the Company has acquired 50% of
BioHemp Naturals ("BioHemp"), a licensed hemp cultivator in the
business of cultivating and distributing CBD-rich hemp biomass to licensed
producers in Canada. BioHemp co-founder, Len Atkinson, will join the MYM
management team as Global Hemp Project Manager.
BioHemp's
founder has been growing hemp since 2015 and developed unique harvesting
methods and standard operating procedures which meet all Health Canada testing
requirements for hemp. BioHemp is expanding its hemp operations to cultivate
450 acres this 2019 season with plans to expand to 3,000 acres of certified
organic hemp in 2020. Forecasted revenues based on the sale of biomass for the
2019 grow season are expected to exceed $30 million with 2020 grow season $225
million.The partnership will allow BioHemp to toll-process the hemp flower
through MYM's planned extraction plant which would significantly increase
revenues for both seasons.
"Acquiring
50% of BioHemp Naturals and engaging Mr. Atkinson as MYM's Global Hemp Project
Manager is a huge win for MYM and our stated goal to become global CBD-rich
hemp cultivators, extractors, and distributors," said Howard Steinberg,
CEO of MYM. "The addition of BioHemp Naturals adds over 3,000 acres of cultivation
to the company which is expected to significantly increase future revenues of
MYM."
Curaleaf Holdings, Inc. (CSE:
CURA) (OTCQX:
CURLF) , a
leading vertically integrated cannabis operator in the United States, unveiled its new Arizona initiative with the
Veterans
Cannabis Project (VCP),
an organization that advocates for legal and supported access of medical
cannabis for veterans through the Department of Veterans Affairs. Patients at
Curaleaf's five Arizona locations can purchase a custom-designed "Veterans
Cannabis Project" pre-roll product, with a portion of all proceeds
benefiting the VCP. Each box includes five pre-rolls and will be available for
$16.
Veterans
and concerned citizens also participated in the launch of a nationwide petition
and grassroots campaign supporting medical cannabis. The campaign urges
Congress to authorize access, provide protections, and require research into
medical cannabis. Additionally, it calls for the Department of Veterans Affairs
to give veterans access to the cannabis they overwhelmingly want and
deserve. The petition can be accessed
here: https://www.vetscp.org/act.
To
celebrate the launch, local veterans visited Curaleaf's Midtown location to
hear Dr. Sue Sisley, an Arizona scientist who conducted the first FDA-approved
study of cannabis for PTSD in veterans, speak about her recent research. Steve
Cottrell, President of Curaleaf Arizona, and Doug Distaso, Executive Director
of VCP, also spoke about the new initiative aimed at raising awareness and
support around veterans' access.
Investor ideas reminds all listeners to read our disclaimers and
disclosures on the
Investorideas.com website and this podcast is not an endorsement
to buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment
Subscribe to the new cannabis podcast series:
Investorideas.com podcasts are also
available on iTunes, Spotify, Google
Play Music, Stitcher, Spreaker, YouTube
via Spreaker, iHeartradio and Tunein.
Potcasts is now a certified word mark Trademark
on the blockchain through Cognate, Inc. CM Certification-Registration Number:
10468217708
About Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com is a recognized news
source publishing third party news and press releases plus we create original
financial content. Learn about investing in stocks and sector trends
from Investorideas.com with our news alerts , articles , podcasts and videos talking about cannabis, crypto,
technology including AI and IoT ,
mining ,sports biotech, water, renewable energy and more . Investorideas.com
original branded content includes the daily Crypto Corner and Podcast, Play
by Play sports and stock news column, Investor Ideas #Potcasts #Cannabis News
and Stocks on the Move podcast and column,
Cleantech and Climate Change Podcast and
the AI
Eye Podcast and column covering developments in
AI.
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of each company directly regarding
specific questions.
More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn
more about publishing your news release and our other news services on the
Investorideas.com newswire https://www.investorideas.com/News-Upload/ and
tickertagstocknews.com
Global investors must adhere to regulations of each
country. Please read Investorideas.com privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of cannabis except where
permissible by law. Our site does not possess, distribute, or sell cannabis
products.
Follow us on Social Media
Contact Investorideas.com
800-665-0411
